Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Xifaxan

This page shows the latest Xifaxan news and features for those working in and with pharma, biotech and healthcare.

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands. ... Xifaxan and Relistor are integral to our gastrointestinal franchise which remains a core asset for future growth potential in the hands of Valeant.".

Latest news

  • FDA approves two new IBS medicines FDA approves two new IBS medicines

    The FDA has approved two new treatments for irritable bowel syndrome with diarrhoea (IBS-D) in the form of Actavis' Viberzi (eluxadoline) and Salix' Xifaxan (rifaximin). ... Xifaxan, an antibiotic derived from rifampin, was previously approved as

  • Valeant raises offer for Salix; rival Endo bows out Valeant raises offer for Salix; rival Endo bows out

    The Canadian company is banking on the future success of Salix' traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), which is in the final stages of FDA review for the ... Analysts have suggested Xifaxan could eventually become a

  • Endo tries to ride out Valeant with $15.7bn bid for Salix Endo tries to ride out Valeant with $15.7bn bid for Salix

    Salix would give it an entry into the gastrointestinal therapy category, bringing in products such as traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), as well as other products like

  • Valeant swoops on Salix with $10bn takeover deal Valeant swoops on Salix with $10bn takeover deal

    Adding Salix to the fold will bring in traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), as well as other products such as diabetes therapy Glumetza (extended-release metformin) that ... Salix is due to report full-year

  • Valeant and Shire said to be evaluating potential Salix bids Valeant and Shire said to be evaluating potential Salix bids

    The problems affected Salix' hepatic encephalopathy therapy Xifaxan (rifaximin) as well as other products such as diabetes therapy Glumetza (extended-release metformin).

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in February 2015 Pharma deals in February 2015

    real interest driver is Xifaxan. ... Xifaxan is currently marketed for the treatment of hepatic encephalopathy and traveller's diarrhoea and nets $750m in sales, however, should the current FDA review for an inflammatory bowel disease with

  • Pharma deals during November 2013 Pharma deals during November 2013

    The all-cash transaction is expected to close in Q1 2014. The combined company will market 22 products, including Xifaxan (rifaximin; 2012 sales of $514.5m) and Santarus' therapy Glumetza (metformin)

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...

Quick links